Fed Sinks Markets
Health Care: Drugs
BioTime Inc. (BTX: AMEX)
$4.02 -0.02 | -0.50%
06/19/13 - 04:03 PM ET
Company Income Statement
| Dec 2012 | Dec 2011 | Dec 2010 | Dec 2009 | |
| Sales | 3.92M | 4.35M | 3.68M | 1.93M |
| Cost of Sales | 434.27K | 0.00 | 0.00 | 0.00 |
| Gross Operating Profit | 3.48M | 4.35M | 3.68M | 1.93M |
| Selling, General, and Administrative Expenses | 10.37M | 9.34M | 5.64M | 2.48M |
| Research & Development | 18.12M | 13.70M | 7.89M | 2.97M |
| Operating Income before D & A (EBITDA) | -25.00M | -18.69M | -9.85M | -3.52M |
| Depreciation & Amortization | 3.07M | 2.91M | 1.40M | 602.95K |
| Interest Income | 19.38K | 29.73K | 0.00 | 0.00 |
| Other Income - Net | -324.57K | 212.82K | -2.21M | 30.70K |
| Special Income / Charges | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Income Before Interest Expenses (EBIT) | -28.38M | -21.35M | -13.47M | -4.09M |
| Interest Expense | 0.00 | 0.00 | 124.30K | 1.65M |
| Pre-Tax Income | -28.38M | -21.35M | -13.59M | -5.75M |
| Income Taxes | 0.00 | 0.00 | 0.00 | 0.00 |
| Minority Interest | -3.88M | -1.93M | -1.00M | 590.00 |
| Net Income From Continuing Operations | -25.31M | 0.00 | 0.00 | 0.00 |
| Net Income From Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income From Total Operations | -25.31M | 0.00 | 0.00 | 0.00 |
| Extraordinary Income/Losses | 0.00 | 0.00 | 0.00 | 0.00 |
| Income From Cum. Effect of Acct. Change | 0.00 | 0.00 | 0.00 | 0.00 |
| Income From Tax Loss Carryforward | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Gains / Losses | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Net Income | -21.43M | -16.52M | -11.18M | -5.14M |
| Normalized Income (Net Income From Continuing Operations, Ex. Special Income / Charge) |
-25.31M | 0.00 | 0.00 | 0.00 |
| Preferred Dividends | ||||
|---|---|---|---|---|
| Net Income Available To Common | -25.31M | 0.00 | 0.00 | 0.00 |
| Basic EPS from Continuing Ops. | -0.44 | -0.35 | -0.28 | -0.18 |
| Basic EPS from Discontinued Ops. | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic EPS from Total Operations | -0.44 | -0.35 | -0.28 | -0.18 |
| Basic EPS from Extraordinary Inc. | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic EPS from Cum Effect of Accounting Change | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic EPS from Tax Loss Carryf'd. | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic EPS from Other Gains (Losses) | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic EPS, Total | -0.44 | -0.35 | -0.28 | -0.18 |
| Basic Normalized Net Income/Share | -0.44 | n.a. | n.a. | n.a. |
| EPS fr Continuing Ops. | -0.44 | -0.35 | -0.28 | -0.18 |
| EPS fr Discontinued Ops | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS fr Total Ops. | -0.44 | -0.35 | -0.28 | -0.18 |
| EPS fr Extraord. Inc. | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS fr Cum Effect of Accounting Change | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS fr Tax Loss Carfd. | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS fr Other Gains (L) | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS, Total | -0.44 | -0.35 | -0.28 | -0.18 |
| Diluted Normalized Net Inc/Shr (Net Income From Continuing Operations, Ex. Special Income / Charge) |
-0.44 | n.a. | n.a. | n.a. |
| Dividends Paid per Share | 0.00 | 0.00 | 0.00 | 0.00 |
Portfolios with BTX
- Portfolio NameUser Type
- ContributorStocks With Big Insider Buy...
- ContributorStocks Under-$10 Moving Hig...
Latest BTX Headlines from TheStreet
- 4 Biotech Stocks Under $10 Moving Higher 02.20.13 | 09:02 pm
Press Releases for BTX
- Hadasit Bio-Holdings Ltd. Portfolio Company - Cell Cure Neurosciences Ltd. Received Additional Government Support - PR Newswire 05.23.13 | 03:05 pm
- PDL BioPharma Appoints Peter Garcia As Chief Financial Officer - PR Newswire 04.30.13 | 04:04 pm
- LifeMap Sciences, A Subsidiary Of BioTime, Announces Release Of LifeMap DiscoveryTM Version 1.1 With Enhanced Therapeutic Discovery And Commercial Utility - Business Wire 03.25.13 | 02:03 pm
- BioTime Announces Fourth Quarter And Fiscal Year End 2012 Financial Results And Recent Corporate Accomplishments - Business Wire 03.18.13 | 04:03 pm
- BioTime To Present At 25th Annual ROTH Conference - Business Wire 03.13.13 | 09:03 am
- BioTime Appoints Stephen C. Farrell To Board Of Directors - Business Wire 03.12.13 | 09:03 am
- BioTime And Romulus Agree To Accelerate Closing Date For Second Tranche Of $5 Million Financing - Business Wire 03.07.13 | 09:03 am
- (Video: Business Wire) - Business Wire 03.04.13 | 09:03 am
- LifeMap Sciences, A Subsidiary Of BioTime, Reports Its Databases Currently Utilized By An Estimated Two Million Unique Visitors Annually According To Google Analytics - Business Wire 02.11.13 | 09:02 am
- BioTime’s Subsidiary OncoCyte Corporation Provides An Update On The Development Of The Novel Pan-Cancer Diagnostic Product PanC-DxTM - Business Wire 01.31.13 | 09:01 am
Partner Headlines for BTX
- Brainstorm's Breakthrough ALS Clinical Data Shows The Promise In Stem Cell Therapy - Seeking Alpha 03.28.13 | 09:03 am
- Geron Posts Narrower Loss - Analyst Blog - Zacks 10.31.12 | 09:10 am
- BioTime: Weak Pipeline Unlikely To Deliver - Seeking Alpha 07.30.12 | 09:07 am
- Earnings Report Card, Regenerative Medicine Universe Edition - Seeking Alpha 08.11.11 | 09:08 am
- Biotime Sees Its Net Loss Widen in Q2 - Seeking Alpha 08.11.11 | 09:08 am
- China Biotech Week in Review: GSK Acquires Urology Drugmaker - Seeking Alpha 12.12.10 | 09:12 am
